Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

(2012) David Croteau et al.   AIDS

Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120

(2011) Lucia Lisi et al.   JOURNAL OF NEUROCHEMISTRY

Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment‐Naive, HIV‐1–Infected Individuals Commencing cART? A Randomized, Controlled Study

(2010) Alan Winston et al.   CLINICAL INFECTIOUS DISEASES

Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy

(2010) Aylin Yilmaz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment

(2010) Arvid Edén et al.   JOURNAL OF INFECTIOUS DISEASES

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

(2009) Aylin Yilmaz et al.   AIDS

G-Protein-Coupled Receptor Screen Reveals a Role for Chemokine Receptor CCR5 in Suppressing Microglial Neurotoxicity

(2008) K. Gamo et al.   JOURNAL OF NEUROSCIENCE